Beacon Biosignals uses AI to accelerate new treatments for neurological and psychiatric diseases.
Beacon Biosignals is listed on Rocketlist with 13 active roles. The company is categorized as Neurotechnology in HealthTech. Beacon Biosignals is at Series B stage, with a B2B and B2C business model, headquartered in Boston, United States. Beacon Biosignals was founded in 2019. Beacon Biosignals has raised $30M. Active roles are refreshed daily from public hiring sources.